Liabilities / Assets
10th percentile
Higher debt load relative to assets than 10% of similar nonprofits.
Institute of Quantitative Systems Pharmacology Iqsp
EIN 81-2862096 • 501(c)3 • Carlsbad, CA
Profile
IQSP's mission is to advance drug development through instruction in and application of quantitative systems pharmacology
Siviq Scores
Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.
0.00x
Liabilities / Revenue
12th percentile
Higher debt load relative to revenue than 12% of similar nonprofits.
Net Margin
92nd percentile
Higher net margin than 92% of similar nonprofits.
Top Officer Pay
23rd percentile
Higher top officer pay than 23% of similar nonprofits.
Top officer pay equals 0.0% of source-year revenue.
Asset Growth
75th percentile
Faster asset growth than 75% of similar nonprofits.
Revenue Growth
43rd percentile
Faster revenue growth than 43% of similar nonprofits.
Balance Sheet
Assets
Up$6,611,143
Up $1,742,087 (+36%) from 2022
Liabilities
Down$1,965
Down $1,777 (-47%) from 2022
Net Assets
Up$6,609,178
Up $1,743,864 (+36%) from 2022
Revenue
Down$1,152,158
Down $77,020 (-6.3%) from 2022
Expenses
Down$447,576
Down $66,243 (-13%) from 2022
Net Income
Down$704,582
Down $10,777 (-1.5%) from 2022
Trend Graphs
Filings
Most recent year
2024 • Form 990Facts available. Structured filing facts are available, but richer extracted sections are limited.
- Assets
- $6,611,143
- Liabilities
- $1,965
- Net assets
- $6,609,178
- Revenue
- $1,152,158
- Expenses
- $447,576
- Net income
- $704,582
Latest Filing Detail
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2024 to Dec 31, 2024
- Signed
- Oct 29, 2025
- Return Version
- 2024v5.2
- Gross Receipts
- $1,152,158
Mission and Program Overview
Mission
IQSP's mission is to advance drug development through instruction in and application of quantitative systems pharmacology
IQSPs mission is to advance drug development through instruction in and application of quantitative systems pharmacology
Balance Sheet Detail
| Line | Beginning | End | Change |
|---|---|---|---|
| Assets | |||
| Investments in Publicly Traded Securities | $5,032,517 | $5,784,382 | ▲ $751,865 |
| Accounts Receivable | $500,000 | $505,000 | ▲ $5,000 |
| Savings and Temporary Cash Investments | $71,513 | $233,386 | ▲ $161,873 |
| Cash and Non-Interest-Bearing Accounts | $131,435 | $88,375 | ▼ $43,060 |
| Total Assets | $5,735,465 | $6,611,143 | ▲ $875,678 |
| Liabilities | |||
| Accounts Payable and Accrued Expenses | $-3,248 | $1,965 | ▲ $5,213 |
| Total Liabilities | $-3,248 | $1,965 | ▲ $5,213 |
| Net Assets / Fund Balance | |||
| Net Assets With Donor Restrictions | $5,299,990 | $6,058,424 | ▲ $758,434 |
| Net Assets Without Donor Restrictions | $438,723 | $550,754 | ▲ $112,031 |
| Total Net Assets Fund Balance | $5,738,713 | $6,609,178 | ▲ $870,465 |
| Total Liabilities and Net Assets / Fund Balance | $5,735,465 | $6,611,143 | ▲ $875,678 |
Compensation and Service Providers
Board Members and Trustees
| Name | Title |
|---|---|
| Jessie L Au Pharmd Phd | Chair |
| Dan Lu Phd | Director |
| Vincent H Lee Phd Dsc | Director |
| M Guillaume Wientjes | Secretary Treasurer |
Revenue and Support
Revenue Composition
- Contributions and Grants
- $865,554
- Program Service Revenue
- $0
- Investment Income
- $286,604
- Other Revenue
- $0
- All Other Contributions
- $689,930
- Change in Net Assets
- $704,582
Expenses and Functional Allocation
Major Expense Lines
| Line Item | Amount |
|---|---|
| Salaries, Compensation, and Employee Benefits | $295,151 |
| Other Expenses | $152,425 |
| Grants and Similar Amounts Paid | $0 |
| Professional Fundraising Fees | $0 |
| Total Fundraising Expense | $0 |
Functional Expense Allocation
| Line Item | Program | Management | Fundraising | Total |
|---|---|---|---|---|
| Other Salaries and Wages | $165,580 | - | - | $165,580 |
| Office Expenses | - | $123,017 | - | $123,017 |
| Current Officers, Directors, Trustees, and Key Employees | $66,972 | $30,566 | - | $97,538 |
| Other Employee Benefits | $19,323 | - | - | $19,323 |
| Payroll Taxes | $12,710 | - | - | $12,710 |
| Insurance | - | $6,230 | - | $6,230 |
| Other Expenses | $5,438 | $3,180 | - | $5,438 |
| Fees for Services Accounting | - | $1,730 | - | $1,730 |
| Advertising | - | $720 | - | $720 |
| Fees for Services Other | - | $400 | - | $400 |
| Total Functional Expenses | $279,735 | $167,841 | $0 | $447,576 |
Fundraising, Events, and Gaming
- Fundraising activities
- No
- Gaming activities
- No
- Professional fundraiser used
- No
Fundraising and Gaming Totals
| Line Item | Amount |
|---|---|
| Professional Fundraising Fees | $0 |
Political and Lobbying Activity
- Political campaign activity
- No
- Lobbying activity
- No
Governance and Compliance
Governance Checklist
- Compiled or reviewed by an accountant
- No
- Annual disclosure for covered persons
- Yes
- Backup withholding compliance
- Yes
- Business relationship with 35% controlled entity
- No
- Business relationship with family members
- No
- Business relationship with organization members
- No
- Material changes to governing documents
- No
- Compensation from other sources disclosed
- No
- CEO compensation reviewed
- Yes
- Other officer compensation reviewed
- Yes
- Conflict-of-interest policy
- Yes
- Audited financial statements prepared
- No
- Key decisions subject to board approval
- No
- Management duties delegated
- No
Governance Explanations
Part VI Line 2
“Jessie Au (Chair) and M Guill Wientjes (Secretary, Treasurer) are married”
Part VI Line 11B
“No review was or will be conducted.”
Part VI Line 12C
“Potential conflicts of interest for all officers and key personnel are”
Part VI Line 12C
“reviewed annually”
Part VI Line 15A or B
“Compensation for performance of officer duties in IQSP is $0”
Part VI Line 19
“IQSP documents are available at: https://rct.doj.ca.gov/ (Reg Ver Search T)”
Part VI Line 19
“Additional documents are available to the public upon request.”
Filing and Contact Details
Filer
- Filer Name
- Institute of Quantitative Systems Pharmacology
- EIN
- 81-2862096
- In Care Of
- % M Guillaume Wientjes
- Phone
- 6145708878
- Address
- 1815 Aston Ave STE STE 107, Carlsbad, CA 92008-7340
- Doing Business As
- Iqsp
Signing Officer
- Name
- M Guillaume Wientjes
- Title
- Secretary
- Phone
- 6145708878
- Signed
- 2025-10-29
Organization Details
- Principal Officer
- M Guillaume Wientjes
- Formed
- 2016
- Legal Domicile
- CA
- Voting Board Members
- 3
- Independent Board Members
- 3
- Employees
- 1
Supplemental Narrative
Additional Explanations
Part XI Line 9
“Rounding”
Part III, line 4A
“PROGRAM ACCOMPLISHMENTS”
Part III, line 4A
“High failure rate in drug development is a factor driving up the”
Part III, line 4A
“health care costs in the US and around the world. The Food and”
Part III, line 4A
“Drug Administration (FDA) and National Institutes of Health”
Part III, line 4A
“(NIH) recognize that increased application of computational”
Part III, line 4A
“modeling, often referred to as Model-Informed Drug Development”
Part III, line 4A
“or Quantitative Systems Pharmacology, will be an important factor”
Part III, line 4A
“leading to smarter drug development processes and better decision”
Part III, line 4A
“making. The NIH even issued a White Paper in 2011 naming”
Part III, line 4A
“establishment of research and teaching programs in quantitative”
Part III, line 4A
“systems pharmacology as a national high priority. The FDA, under”
Part III, line 4A
“the 2017 FDA Reauthorization Act, has committed to adopting”
Part III, line 4A
“Model-Informed Drug Development (MIDD) in regulatory consideration”
Part III, line 4A
“of applications for new drugs and generic drugs.”
Part III, line 4A
“Quantitative Systems Pharmacology (QSP) uses”
Part III, line 4A
“computational modeling to gain or enhance understanding of”
Part III, line 4A
“biological systems. MIDD is a sub-area of QSP and refers to using”
Part III, line 4A
“quantitative models to facilitate the decision-making process and”
Part III, line 4A
“address drug development and regulatory questions in four”
Part III, line 4A
“categories: dose optimization, supportive evidence for efficacy,”
Part III, line 4A
“clinical trial design, and informing policy. MIDD is multidisciplinary”
Part III, line 4A
“and requires knowledge in diverse fields including biology, physics,”
Part III, line 4A
“chemistry, pharmacology, pharmaceutical sciences, computational”
Part III, line 4A
“modeling, clinical sciences, and regulatory sciences. IQSP pursues”
Part III, line 4A
“research and training in various areas of QSP and MIDD.”
Part III, line 4A
“Research in support of FDA contract award 75F40119C10139 was”
Part III, line 4A
“performed.”
Raw XML Appendix382 raw XML fields
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990/AccountantCompileOrReviewInd | 0 | false |
| IRS990/AccountsPayableAccrExpnssGrp/BOYAmt | 0 | -3248 |
| IRS990/AccountsPayableAccrExpnssGrp/EOYAmt | 0 | 1965 |
| IRS990/AccountsReceivableGrp/BOYAmt | 0 | 500000 |
| IRS990/AccountsReceivableGrp/EOYAmt | 0 | 505000 |
| IRS990/ActivitiesConductedPrtshpInd | 0 | false |
| IRS990/ActivityOrMissionDesc | 0 | IQSPs mission is to advance drug development through instruction in and application of quantitative systems pharmacology |
| IRS990/AdvertisingGrp/ManagementAndGeneralAmt | 0 | 720 |
| IRS990/AdvertisingGrp/TotalAmt | 0 | 720 |
| IRS990/AllOtherContributionsAmt | 0 | 689930 |
| IRS990/AnnualDisclosureCoveredPrsnInd | 0 | true |
| IRS990/BackupWthldComplianceInd | 0 | true |
| IRS990/BooksInCareOfDetail/PersonNm | 0 | M GUILLAUME WIENTJES |
| IRS990/BooksInCareOfDetail/PhoneNum | 0 | 6145708878 |
| IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 1815 Aston Ave |
| IRS990/BooksInCareOfDetail/USAddress/CityNm | 0 | Carlsbad |
| IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | CA |
| IRS990/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 920087340 |
| IRS990/BusinessRlnWith35CtrlEntInd | 0 | false |
| IRS990/BusinessRlnWithFamMemInd | 0 | false |
| IRS990/BusinessRlnWithOrgMemInd | 0 | false |
| IRS990/CashNonInterestBearingGrp/BOYAmt | 0 | 131435 |
| IRS990/CashNonInterestBearingGrp/EOYAmt | 0 | 88375 |
| IRS990/ChangeToOrgDocumentsInd | 0 | false |
| IRS990/CollectionsOfArtInd | 0 | false |
| IRS990/CompCurrentOfcrDirectorsGrp/ManagementAndGeneralAmt | 0 | 30566 |
| IRS990/CompCurrentOfcrDirectorsGrp/ProgramServicesAmt | 0 | 66972 |
| IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt | 0 | 97538 |
| IRS990/CompensationFromOtherSrcsInd | 0 | false |
| IRS990/CompensationProcessCEOInd | 0 | true |
| IRS990/CompensationProcessOtherInd | 0 | true |
| IRS990/ConflictOfInterestPolicyInd | 0 | true |
| IRS990/ConservationEasementsInd | 0 | false |
| IRS990/ConsolidatedAuditFinclStmtInd | 0 | false |
| IRS990/CreditCounselingInd | 0 | false |
| IRS990/CYBenefitsPaidToMembersAmt | 0 | 0 |
| IRS990/CYContributionsGrantsAmt | 0 | 865554 |
| IRS990/CYGrantsAndSimilarPaidAmt | 0 | 0 |
| IRS990/CYInvestmentIncomeAmt | 0 | 286604 |
| IRS990/CYOtherExpensesAmt | 0 | 152425 |
| IRS990/CYOtherRevenueAmt | 0 | 0 |
| IRS990/CYProgramServiceRevenueAmt | 0 | 0 |
| IRS990/CYRevenuesLessExpensesAmt | 0 | 704582 |
| IRS990/CYSalariesCompEmpBnftPaidAmt | 0 | 295151 |
| IRS990/CYTotalExpensesAmt | 0 | 447576 |
| IRS990/CYTotalFundraisingExpenseAmt | 0 | 0 |
| IRS990/CYTotalProfFndrsngExpnsAmt | 0 | 0 |
| IRS990/CYTotalRevenueAmt | 0 | 1152158 |
| IRS990/DecisionsSubjectToApprovaInd | 0 | false |
| IRS990/DeductibleArtContributionInd | 0 | false |
| IRS990/DeductibleNonCashContriInd | 0 | false |
| IRS990/DelegationOfMgmtDutiesInd | 0 | false |
| IRS990/Desc | 0 | See Schedule O |
| IRS990/DescribedInSection501c3Ind | 0 | true |
| IRS990/DisregardedEntityInd | 0 | false |
| IRS990/DocumentRetentionPolicyInd | 0 | true |
| IRS990/DoingBusinessAsName/BusinessNameLine1Txt | 0 | IQSP |
| IRS990/DonorAdvisedFundInd | 0 | false |
| IRS990/DonorRestrictionNetAssetsGrp/BOYAmt | 0 | 5299990 |
| IRS990/DonorRestrictionNetAssetsGrp/EOYAmt | 0 | 6058424 |
| IRS990/DonorRstrOrQuasiEndowmentsInd | 0 | false |
| IRS990/ElectionOfBoardMembersInd | 0 | false |
| IRS990/EmployeeCnt | 0 | 1 |
| IRS990/EmploymentTaxReturnsFiledInd | 0 | true |
| IRS990/EngagedInExcessBenefitTransInd | 0 | false |
| IRS990/ExpenseAmt | 0 | 279736 |
| IRS990/FamilyOrBusinessRlnInd | 0 | true |
| IRS990/FederalGrantAuditRequiredInd | 0 | false |
| IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt | 0 | 1730 |
| IRS990/FeesForServicesAccountingGrp/TotalAmt | 0 | 1730 |
| IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt | 0 | 400 |
| IRS990/FeesForServicesOtherGrp/TotalAmt | 0 | 400 |
| IRS990/ForeignActivitiesInd | 0 | false |
| IRS990/ForeignFinancialAccountInd | 0 | false |
| IRS990/ForeignOfficeInd | 0 | false |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt | 0 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt | 1 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt | 2 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt | 3 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 0 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 1 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 2 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt | 3 | 0.00 |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 0 | X |
| IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd | 1 | X |
| IRS990/Form990PartVIISectionAGrp/OfficerInd | 0 | X |
| IRS990/Form990PartVIISectionAGrp/OfficerInd | 1 | X |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 0 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 1 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 2 | 0 |
| IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt | 3 | 0 |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 0 | VINCENT H LEE PHD DSC |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 1 | DAN LU PHD |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 2 | JESSIE L AU PHARMD PHD |
| IRS990/Form990PartVIISectionAGrp/PersonNm | 3 | M GUILLAUME WIENTJES |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 0 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 1 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 2 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt | 3 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 0 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 1 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 2 | 0 |
| IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt | 3 | 0 |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 0 | Director |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 1 | Director |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 2 | Chair |
| IRS990/Form990PartVIISectionAGrp/TitleTxt | 3 | Secretary Treasurer |
| IRS990/Form990ProvidedToGvrnBodyInd | 0 | false |
| IRS990/FormationYr | 0 | 2016 |
| IRS990/FormerOfcrEmployeesListedInd | 0 | false |
| IRS990/FSAuditedInd | 0 | false |
| IRS990/FundraisingActivitiesInd | 0 | false |
| IRS990/GamingActivitiesInd | 0 | false |
| IRS990/GoverningBodyVotingMembersCnt | 0 | 3 |
| IRS990/GovernmentGrantsAmt | 0 | 175624 |
| IRS990/GrantsToIndividualsInd | 0 | false |
| IRS990/GrantsToOrganizationsInd | 0 | false |
| IRS990/GrantToRelatedPersonInd | 0 | false |
| IRS990/GrossReceiptsAmt | 0 | 1152158 |
| IRS990/GroupReturnForAffiliatesInd | 0 | false |
| IRS990/IncludeFIN48FootnoteInd | 0 | false |
| IRS990/IndependentAuditFinclStmtInd | 0 | false |
| IRS990/IndependentVotingMemberCnt | 0 | 3 |
| IRS990/IndivRcvdGreaterThan100KCnt | 0 | 1 |
| IRS990/IndoorTanningServicesInd | 0 | false |
| IRS990/InfoInScheduleOPartIIIInd | 0 | X |
| IRS990/InfoInScheduleOPartVIInd | 0 | X |
| IRS990/InfoInScheduleOPartXIInd | 0 | X |
| IRS990/InsuranceGrp/ManagementAndGeneralAmt | 0 | 6230 |
| IRS990/InsuranceGrp/TotalAmt | 0 | 6230 |
| IRS990/InvestmentIncomeGrp/ExclusionAmt | 0 | 286604 |
| IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt | 0 | 286604 |
| IRS990/InvestmentInJointVentureInd | 0 | false |
| IRS990/InvestmentsPubTradedSecGrp/BOYAmt | 0 | 5032517 |
| IRS990/InvestmentsPubTradedSecGrp/EOYAmt | 0 | 5784382 |
| IRS990/IRPDocumentCnt | 0 | 0 |
| IRS990/IRPDocumentW2GCnt | 0 | 0 |
| IRS990/LandBldgEquipAccumDeprecAmt | 0 | 77072 |
| IRS990/LandBldgEquipCostOrOtherBssAmt | 0 | 77072 |
| IRS990/LegalDomicileStateCd | 0 | CA |
| IRS990/LoanOutstandingInd | 0 | false |
| IRS990/LobbyingActivitiesInd | 0 | false |
| IRS990/LocalChaptersInd | 0 | false |
| IRS990/MaterialDiversionOrMisuseInd | 0 | false |
| IRS990/MembersOrStockholdersInd | 0 | false |
| IRS990/MethodOfAccountingCashInd | 0 | X |
| IRS990/MinutesOfCommitteesInd | 0 | true |
| IRS990/MinutesOfGoverningBodyInd | 0 | true |
| IRS990/MissionDesc | 0 | IQSP's mission is to advance drug development through instruction in and application of quantitative systems pharmacology |
| IRS990/MoreThan5000KToIndividualsInd | 0 | false |
| IRS990/MoreThan5000KToOrgInd | 0 | false |
| IRS990/NetAssetsOrFundBalancesBOYAmt | 0 | 5738713 |
| IRS990/NetAssetsOrFundBalancesEOYAmt | 0 | 6609178 |
| IRS990/NetIncmFromFundraisingEvtGrp/TotalRevenueColumnAmt | 0 | 0 |
| IRS990/NetUnrelatedBusTxblIncmAmt | 0 | 0 |
| IRS990/NetUnrlzdGainsLossesInvstAmt | 0 | 165885 |
| IRS990/NoDonorRestrictionNetAssetsGrp/BOYAmt | 0 | 438723 |
| IRS990/NoDonorRestrictionNetAssetsGrp/EOYAmt | 0 | 550754 |
| IRS990/NoListedPersonsCompensatedInd | 0 | X |
| IRS990/NondeductibleContributionsInd | 0 | false |
| IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt | 0 | 123017 |
| IRS990/OfficeExpensesGrp/TotalAmt | 0 | 123017 |
| IRS990/OfficerMailingAddressInd | 0 | false |
| IRS990/OperateHospitalInd | 0 | false |
| IRS990/Organization501c3Ind | 0 | X |
| IRS990/OrganizationFollowsFASB117Ind | 0 | X |
| IRS990/OtherChangesInNetAssetsAmt | 0 | -2 |
| IRS990/OtherEmployeeBenefitsGrp/ProgramServicesAmt | 0 | 19323 |
| IRS990/OtherEmployeeBenefitsGrp/TotalAmt | 0 | 19323 |
| IRS990/OtherExpensesGrp/Desc | 0 | Materials and supplies |
| IRS990/OtherExpensesGrp/Desc | 1 | Dues and subscriptions |
| IRS990/OtherExpensesGrp/Desc | 2 | Consortiumsubcontracts |
| IRS990/OtherExpensesGrp/ManagementAndGeneralAmt | 0 | 1998 |
| IRS990/OtherExpensesGrp/ManagementAndGeneralAmt | 1 | 3180 |
| IRS990/OtherExpensesGrp/ProgramServicesAmt | 0 | 9712 |
| IRS990/OtherExpensesGrp/ProgramServicesAmt | 1 | 5438 |
| IRS990/OtherExpensesGrp/TotalAmt | 0 | 11710 |
| IRS990/OtherExpensesGrp/TotalAmt | 1 | 3180 |
| IRS990/OtherExpensesGrp/TotalAmt | 2 | 5438 |
| IRS990/OtherSalariesAndWagesGrp/ProgramServicesAmt | 0 | 165580 |
| IRS990/OtherSalariesAndWagesGrp/TotalAmt | 0 | 165580 |
| IRS990/PartialLiquidationInd | 0 | false |
| IRS990/PayrollTaxesGrp/ProgramServicesAmt | 0 | 12710 |
| IRS990/PayrollTaxesGrp/TotalAmt | 0 | 12710 |
| IRS990/PoliticalCampaignActyInd | 0 | false |
| IRS990/PrincipalOfficerNm | 0 | M Guillaume Wientjes |
| IRS990/ProfessionalFundraisingInd | 0 | false |
| IRS990/ProhibitedTaxShelterTransInd | 0 | false |
| IRS990/PYContributionsGrantsAmt | 0 | 866660 |
| IRS990/PYExcessBenefitTransInd | 0 | false |
| IRS990/PYInvestmentIncomeAmt | 0 | 242255 |
| IRS990/PYOtherExpensesAmt | 0 | 148524 |
| IRS990/PYRevenuesLessExpensesAmt | 0 | 665168 |
| IRS990/PYSalariesCompEmpBnftPaidAmt | 0 | 295223 |
| IRS990/PYTotalExpensesAmt | 0 | 443747 |
| IRS990/PYTotalRevenueAmt | 0 | 1108915 |
| IRS990/ReconcilationRevenueExpnssAmt | 0 | 704582 |
| IRS990/RegularMonitoringEnfrcInd | 0 | true |
| IRS990/RelatedEntityInd | 0 | false |
| IRS990/RelatedOrganizationCtrlEntInd | 0 | false |
| IRS990/ReportInvestmentsOtherSecInd | 0 | false |
| IRS990/ReportLandBuildingEquipmentInd | 0 | false |
| IRS990/ReportOtherAssetsInd | 0 | false |
| IRS990/ReportOtherLiabilitiesInd | 0 | false |
| IRS990/ReportProgramRelatedInvstInd | 0 | false |
| IRS990/SavingsAndTempCashInvstGrp/BOYAmt | 0 | 71513 |
| IRS990/SavingsAndTempCashInvstGrp/EOYAmt | 0 | 233386 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt | 0 | 865554 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt | 0 | 866660 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 1196189 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 1156315 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 1164925 |
| IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt | 0 | 5249643 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt | 0 | 286604 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt | 0 | 242255 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 32989 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 118778 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 68262 |
| IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt | 0 | 748888 |
| IRS990ScheduleA/PublicOrganization170Ind | 0 | X |
| IRS990ScheduleA/PublicSupportCY170Pct | 0 | 0.38060 |
| IRS990ScheduleA/PublicSupportPY170Pct | 0 | 0.40405 |
| IRS990ScheduleA/PublicSupportTotal170Amt | 0 | 2282901 |
| IRS990ScheduleA/SubstantialContributorsTotAmt | 0 | 2966742 |
| IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind | 0 | X |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt | 0 | 865554 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt | 0 | 866660 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt | 0 | 1196189 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt | 0 | 1156315 |
| IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt | 0 | 1164925 |
| IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt | 0 | 5249643 |
| IRS990ScheduleA/TotalSupportAmt | 0 | 5998531 |
| IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorNum | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine1 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine2 | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode | 0 | RESTRICTED |
| IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt | 0 | RESTRICTED |
| IRS990/ScheduleBRequiredInd | 0 | true |
| IRS990/ScheduleJRequiredInd | 0 | false |
| IRS990/ScheduleORequiredInd | 0 | true |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 0 | Jessie Au (Chair) and M Guill Wientjes (Secretary, Treasurer) are married |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 1 | No review was or will be conducted. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 2 | Potential conflicts of interest for all officers and key personnel are |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 3 | reviewed annually |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 4 | Compensation for performance of officer duties in IQSP is $0 |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 5 | IQSP documents are available at: https://rct.doj.ca.gov/ (Reg Ver Search T) |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 6 | Additional documents are available to the public upon request. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 7 | Rounding |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 8 | PROGRAM ACCOMPLISHMENTS |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 9 | High failure rate in drug development is a factor driving up the |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 10 | health care costs in the US and around the world. The Food and |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 11 | Drug Administration (FDA) and National Institutes of Health |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 12 | (NIH) recognize that increased application of computational |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 13 | modeling, often referred to as Model-Informed Drug Development |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 14 | or Quantitative Systems Pharmacology, will be an important factor |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 15 | leading to smarter drug development processes and better decision |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 16 | making. The NIH even issued a White Paper in 2011 naming |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 17 | establishment of research and teaching programs in quantitative |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 18 | systems pharmacology as a national high priority. The FDA, under |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 19 | the 2017 FDA Reauthorization Act, has committed to adopting |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 20 | Model-Informed Drug Development (MIDD) in regulatory consideration |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 21 | of applications for new drugs and generic drugs. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 22 | Quantitative Systems Pharmacology (QSP) uses |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 23 | computational modeling to gain or enhance understanding of |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 24 | biological systems. MIDD is a sub-area of QSP and refers to using |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 25 | quantitative models to facilitate the decision-making process and |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 26 | address drug development and regulatory questions in four |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 27 | categories: dose optimization, supportive evidence for efficacy, |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 28 | clinical trial design, and informing policy. MIDD is multidisciplinary |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 29 | and requires knowledge in diverse fields including biology, physics, |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 30 | chemistry, pharmacology, pharmaceutical sciences, computational |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 31 | modeling, clinical sciences, and regulatory sciences. IQSP pursues |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 32 | research and training in various areas of QSP and MIDD. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 33 | Research in support of FDA contract award 75F40119C10139 was |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 34 | performed. |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | Part VI Line 2 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 1 | Part VI Line 11b |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 2 | Part VI Line 12c |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 3 | Part VI Line 12c |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 4 | Part VI Line 15a or b |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 5 | Part VI Line 19 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 6 | Part VI Line 19 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 7 | Part XI Line 9 |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 8 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 9 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 10 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 11 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 12 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 13 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 14 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 15 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 16 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 17 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 18 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 19 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 20 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 21 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 22 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 23 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 24 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 25 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 26 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 27 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 28 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 29 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 30 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 31 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 32 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 33 | Part III, line 4a |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 34 | Part III, line 4a |
| IRS990/SchoolOperatingInd | 0 | false |
| IRS990/SignificantChangeInd | 0 | false |
| IRS990/SignificantNewProgramSrvcInd | 0 | false |
| IRS990/StatesWhereCopyOfReturnIsFldCd | 0 | CA |
| IRS990/SubjectToExcsTaxNetInvstIncInd | 0 | false |
| IRS990/SubjToTaxRmnrtnExPrchtPymtInd | 0 | false |
| IRS990/TaxablePartyNotificationInd | 0 | false |
| IRS990/TaxExemptBondsInd | 0 | false |
| IRS990/TerminateOperationsInd | 0 | false |
| IRS990/TotalAssetsBOYAmt | 0 | 5735465 |
| IRS990/TotalAssetsEOYAmt | 0 | 6611143 |
| IRS990/TotalAssetsGrp/BOYAmt | 0 | 5735465 |
| IRS990/TotalAssetsGrp/EOYAmt | 0 | 6611143 |
| IRS990/TotalCompGreaterThan150KInd | 0 | false |
| IRS990/TotalContributionsAmt | 0 | 865554 |
| IRS990/TotalEmployeeCnt | 0 | 1 |
| IRS990/TotalFunctionalExpensesGrp/FundraisingAmt | 0 | 0 |
| IRS990/TotalFunctionalExpensesGrp/ManagementAndGeneralAmt | 0 | 167841 |
| IRS990/TotalFunctionalExpensesGrp/ProgramServicesAmt | 0 | 279735 |
| IRS990/TotalFunctionalExpensesGrp/TotalAmt | 0 | 447576 |
| IRS990/TotalGrossUBIAmt | 0 | 0 |
| IRS990/TotalLiabilitiesBOYAmt | 0 | -3248 |
| IRS990/TotalLiabilitiesEOYAmt | 0 | 1965 |
| IRS990/TotalLiabilitiesGrp/BOYAmt | 0 | -3248 |
| IRS990/TotalLiabilitiesGrp/EOYAmt | 0 | 1965 |
| IRS990/TotalNetAssetsFundBalanceGrp/BOYAmt | 0 | 5738713 |
| IRS990/TotalNetAssetsFundBalanceGrp/EOYAmt | 0 | 6609178 |
| IRS990/TotalOtherCompensationAmt | 0 | 0 |
| IRS990/TotalProgramServiceExpensesAmt | 0 | 279736 |
| IRS990/TotalReportableCompFromOrgAmt | 0 | 0 |
| IRS990/TotalRevenueGrp/ExclusionAmt | 0 | 286604 |
| IRS990/TotalRevenueGrp/RelatedOrExemptFuncIncomeAmt | 0 | 0 |
| IRS990/TotalRevenueGrp/TotalRevenueColumnAmt | 0 | 1152158 |
| IRS990/TotalRevenueGrp/UnrelatedBusinessRevenueAmt | 0 | 0 |
| IRS990/TotLiabNetAssetsFundBalanceGrp/BOYAmt | 0 | 5735465 |
| IRS990/TotLiabNetAssetsFundBalanceGrp/EOYAmt | 0 | 6611143 |
| IRS990/TotReportableCompRltdOrgAmt | 0 | 0 |
| IRS990/TrnsfrExmptNonChrtblRltdOrgInd | 0 | false |
| IRS990/TypeOfOrganizationCorpInd | 0 | X |
| IRS990/UnrelatedBusIncmOverLimitInd | 0 | false |
| IRS990/UponRequestInd | 0 | X |
| IRS990/USAddress/AddressLine1Txt | 0 | 1815 Aston Ave Ste STE 107 |
| IRS990/USAddress/CityNm | 0 | Carlsbad |
| IRS990/USAddress/StateAbbreviationCd | 0 | CA |
| IRS990/USAddress/ZIPCd | 0 | 920087340 |
| IRS990/VotingMembersGoverningBodyCnt | 0 | 3 |
| IRS990/VotingMembersIndependentCnt | 0 | 3 |
| IRS990/WebsiteAddressTxt | 0 | https://i-qsp.org/ |
| IRS990/WhistleblowerPolicyInd | 0 | true |
| ReturnHeader/BuildTS | 0 | 2025-03-06 01:10:19Z |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | M GUILLAUME WIENTJES |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | Secretary |
| ReturnHeader/BusinessOfficerGrp/PhoneNum | 0 | 6145708878 |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2025-10-29 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | Institute of Quantitative Systems Pharmacology |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | INST |
| ReturnHeader/Filer/EIN | 0 | 812862096 |
| ReturnHeader/Filer/InCareOfNm | 0 | % M Guillaume Wientjes |
| ReturnHeader/Filer/PhoneNum | 0 | 6145708878 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | 1815 Aston Ave STE STE 107 |
| ReturnHeader/Filer/USAddress/CityNm | 0 | Carlsbad |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | CA |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 920087340 |
| ReturnHeader/IRSResponsiblePrtyInfoCurrInd | 0 | true |
| ReturnHeader/ReturnTs | 0 | 2025-10-29T00:04:19-05:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990 |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2024-01-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2024-12-31 |
| ReturnHeader/TaxYr | 0 | 2024 |
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Peer Organizations
Similar nonprofits based on the same Siviq industry and scale cohort. 501(c)3 • $5M-$10M nonprofits
The Woodlands, TX
View OrganizationPediatric Academic Societies Inc
501(c)3
Revenue$6,611,298
Assets$2,350,880
Revenue vs current organization
474% higherAssets vs current organization
64% lowerSouth Bend, IN
View OrganizationSt Margarets House
501(c)3
Revenue$5,223,810
Assets$6,611,383
Revenue vs current organization
353% higherAssets vs current organization
About the sameHarrisonburg, VA
View OrganizationRockingham-Harrisonburg Spca
501(c)3
Revenue$2,385,472
Assets$6,611,790
Revenue vs current organization
107% higherAssets vs current organization
About the sameTyler, TX
View OrganizationThe Park of East Texas Inc
501(c)3
Revenue$1,964,350
Assets$6,611,946
Revenue vs current organization
70% higherAssets vs current organization
About the same